Results 31 to 40 of about 25,812 (159)
THPO-MPL pathway and bone marrow failure
Single or multilineage bone marrow failure can be a serious health problem caused by hereditary and non-hereditary causes such as exposure to drugs or environmental toxins.
Majed Dasouki, Irfan Saadi, Syed O Ahmed
doaj +1 more source
Essential thrombocythemia [PDF]
Review on Essential thrombocythemia, with data on clinics, and the genes ...
Huret, JL
core +1 more source
Does Reactive Thrombocytosis Observed in Iron Deficiency Anemia Affect Plasma Viscosity?
OBJECTIVE: The accompanying thrombocytosis is referred to as the major factor associated with thromboembolism in iron deficiency anemia (IDA). Increased viscosity may increase the risk of thrombosis.
Selami K. Toprak +4 more
doaj +1 more source
Retinal neovascularization in the setting of -mutation positive essential thrombocythemia
Patients with Calreticulin ( CALR ) mutation positive essential thrombocythemia are often thought of as having a “low-risk” of thrombotic complications.
Stanton P Heydinger +2 more
doaj +1 more source
Clinicopathologic Characteristics of Somatic <i>TP53</i> Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review. [PDF]
ABSTRACT Background TP53 mutations (TP53m) are uncommon in chronic‐phase Ph–negative myeloproliferative neoplasms but become enriched in myelofibrosis (MF) and accelerated/blast phase myeloproliferative (AP/BP‐MPN). Their prevalence, allelic distribution, and phase‐stratified outcomes have not been systematically synthesized.
Aldapt M +9 more
europepmc +2 more sources
Thromboembolic complication in Essential Thrombocythemia
The presenting symptoms of patients with essntial thrombocythemia are quite variable. After detection of thrombocytosis about 13 to 37 percent of patients relate symptoms due to hemorrhagic event, and about 22 to 84 percent of patients report ...
Zahra Mozaheb
doaj +1 more source
Exposure-Response Analyses of Ropeginterferon Alfa-2b in Essential Thrombocythemia. [PDF]
Abstract Ropeginterferon alfa‐2b is a new‐generation interferon therapy for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). This investigation was designed to characterize its population pharmacokinetics–pharmacodynamics (PopPK‐PD) and delineate exposure–response (E‐R) relationships in ET. A population PK
Qin A +20 more
europepmc +2 more sources
Genetic studies of hereditary thrombocythemia [PDF]
Hereditary thrombocythemia (HT) is a familial myeloproliferative disorder characterized by an elevated platelet count in peripheral blood. Thrombocytosis is due to a genetic alteration that can be transmitted to the offspring.
Pianta, Annalisa
core +1 more source
Late‐Onset Chorea in JAK2‐Associated Essential Thrombocythemia [PDF]
Somatic mutations in JAK2 are associated with chronic myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis (PMF).
Mulroy, E +17 more
core +2 more sources
We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia.
François Girodon +8 more
doaj +1 more source

